MCF-7 cancer cells-proline dithiocarbamate complex

The term MCF-7 cancer cells-proline dithiocarbamate complex does not refer to a single biological target or receptor, but rather describes an experimental system involving the MCF-7 human breast adenocarcinoma cell line and proline dithiocarbamate (PDTC) ligands or their metal-based derivatives. MCF-7 is a widely utilized model for studying estrogen receptor-positive breast cancer (Soule et al., 1973, Journal of the National Cancer Institute). Proline dithiocarbamate is a chemical derivative often used to form stable complexes with transition metals like Gold(III) or Platinum(II), which are investigated for their potent anticancer properties (Ronconi et al., 2005, Chemistry & Biology). These complexes typically exert their effects by inhibiting the 26S proteasome and modulating redox-sensitive signaling pathways, such as NF-kappaB, to trigger programmed cell death. Because this entry combines a specific cell line with a chemical agent, it is classified as an incorrect target designation in a therapeutic context, representing instead a drug-cell interaction study.

Other names

MCF-7 cells treated with proline dithiocarbamateGold(III) L-proline dithiocarbamate complexPlatinum(II) L-proline dithiocarbamate complexPDTC-metal complexes

The complex acts by inhibiting the 26S proteasome activity, leading to the accumulation of ubiquitinated proteins and the subsequent induction of mitochondrial-mediated apoptosis in cancer cells (Milacic et al., 2006, Cancer Research).